Shana Neal, Executive Vice President and Chief People Officer at Becton Dickinson & Co (NYSE:BDX), recently sold shares in the company according to a regulatory filing. On January 21, Neal sold 787 shares of common stock at a price of $240.00 per share, amounting to a total transaction value of $188,880. Following this sale, Neal retains ownership of 15,414 shares in the company. The transaction was executed under a pre-established Rule 10b5-1 trading plan, which was adopted on September 6, 2024. With the stock trading near its 52-week high and showing overbought signals, InvestingPro subscribers have access to 12 additional investment tips and a comprehensive Pro Research Report for deeper analysis of BDX's current market position.
In other recent news, Becton Dickinson (BD), a leading medical technology firm, reported strong financial results in its Q4 and Full-Year Fiscal 2024 Earnings Call. The company noted a revenue growth of 7.4% in Q4 and a full-year organic revenue increase of 5%. Adjusted diluted earnings per share (EPS) rose by 11.4%, reaching $13.14 for the year. Despite challenges in China and the Bioscience-Pharma sector, BD's MedTech and Diagnostics segments showed significant growth, with BD Medical (TASE:PMCN)'s biologic drug delivery sales exceeding $1 billion.
In addition, BD announced a $1 billion share repurchase plan and a 9.5% dividend increase. For the upcoming fiscal year, the company anticipates revenue between $21.9 billion and $22.1 billion, with an adjusted diluted EPS guidance of $14.25 to $14.60. However, the company expects a mid-single-digit decline in China due to value-based procurement pressures.
BD's management also discussed the integration of the Advanced Patient Monitoring business and its potential for 6% to 7% growth. They outlined capital allocation strategies, including the share repurchase plan and a dividend increase. These recent developments underscore BD's commitment to growth and strategic capital allocation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.